Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF-mutated Metastatic Melanoma”

82 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 82 results

Post-approval studies (Phase 4)Ended earlyNCT01683188
What this trial is testing

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Clinigen, Inc. 53
Testing effectiveness (Phase 2)UnknownNCT03514901
What this trial is testing

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Who this might be right for
Melanoma MetastaticBRAF V600 Mutation
Intergruppo Melanoma Italiano 120
Early research (Phase 1)Ended earlyNCT03332589
What this trial is testing

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Who this might be right for
Malignant MelanomaBrain Metastases
Spirita Oncology, LLC 4
Post-approval studies (Phase 4)Looking for participantsNCT03340506
What this trial is testing

Dabrafenib and/or Trametinib Rollover Study

Who this might be right for
MelanomaNon Small Cell Lung CancerSolid Tumor+2 more
Novartis Pharmaceuticals 100
Early research (Phase 1)Study completedNCT01910181
What this trial is testing

Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 46
Early research (Phase 1)Ended earlyNCT01876641
What this trial is testing

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

Who this might be right for
Metastatic MelanomaMelanomaBRAF-mutated Metastatic Melanoma+1 more
Mohammed M Milhem 18
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Not applicableStudy completedNCT05260684
What this trial is testing

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Who this might be right for
Melanoma
Pfizer 716
Early research (Phase 1)Study completedNCT01673737
What this trial is testing

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

Who this might be right for
Neoplasm Malignant
Sanofi 75
Testing effectiveness (Phase 2)Study completedNCT02631447
What this trial is testing

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

Who this might be right for
Metastatic Melanoma
Fondazione Melanoma Onlus 251
Early research (Phase 1)WithdrawnNCT04759846
What this trial is testing

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Who this might be right for
BRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more
Pierre Fabre Medicament
Early research (Phase 1)Looking for participantsNCT04903119
What this trial is testing

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Who this might be right for
Metastatic MelanomaBRAF Gene Mutation
Rina Plattner 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557956
What this trial is testing

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Who this might be right for
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma
National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Ended earlyNCT04655157
What this trial is testing

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Who this might be right for
Melanoma
Jason J. Luke, MD 2
Early research (Phase 1)Study completedNCT05003622
What this trial is testing

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Who this might be right for
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Pierre Fabre Medicament 3
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19
Testing effectiveness (Phase 2)Ended earlyNCT05926960
What this trial is testing

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Who this might be right for
Melanoma
Pfizer 38
Early research (Phase 1)UnknownNCT05103891
What this trial is testing

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Who this might be right for
MelanomaBRAF V600 MutationUnresectable Melanoma+1 more
Pierre Fabre Medicament 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT02910700
What this trial is testing

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Who this might be right for
Metastatic Malignant Neoplasm in the BrainMetastatic MelanomaStage III Cutaneous Melanoma AJCC v7+5 more
M.D. Anderson Cancer Center 52
Testing effectiveness (Phase 2)Study completedNCT00866177
What this trial is testing

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma
National Cancer Institute (NCI) 167
Load More Results